ERBB2 and non-small cell lung carcinoma: In this regard, two drugs, pertuzumab and trastuzumab, which have been approved for HER2 + breast cancer, have been used in clinical trials, but more studies are needed to confirm their therapeutic effect on NSCLC [179–181].